logo-loader
viewVolitionRx

VolitionRx cancer diagnostic test achieves CE Marking, preps for Europe launch

VolitionRx Limited (NYSEMKT:VNRX) shares jumped 4.4% on Tuesday after the company said it achieved CE marking on its Nu.QTM Colorectal Cancer Screening Triage Test on December 28, paving the way for its expected launch across the European Union.

CancerHeadline.jpg
VolitionRx gets EU green light

VolitionRx Limited (NYSEMKT:VNRX) shares jumped 4.4% on Tuesday after the company said it achieved CE marking on its Nu.QTM Colorectal Cancer Screening Triage Test on December 28, paving the way for its expected launch across the European Union.

The novel blood test, developed at Volition's laboratories in Belgium in conjunction with Hvidovre Hospital (University of Copenhagen), has demonstrated the potential to reduce colonoscopies by up to 25% while maintaining almost 97% detection of colorectal cancer when combined with the fecal immunochemical test (FIT) score. The Nu.QTM Triage Test is the first in a pipeline of cancer screening tests that Volition hopes to bring to market.

"This is a very exciting time for Volition as we are coming to market with a product that we believe meets a pressing and immediate need in many European countries. This is easily our biggest achievement yet, and is the result of many years of work from our dedicated team. This milestone signals our transition from a research and development phase to a commercial one,” said Cameron Reynolds, CEO of Volition.

The most frequently used first line test for colorectal cancer screening across Europe is the FIT test. Patients with a positive score following FIT are then referred for colonoscopy. However, approximately 94.8% of people who test FIT positive do not have colorectal cancer.

This means that there are a significant number of unnecessary expensive and invasive colonoscopies performed, placing a severe burden on both the patient and the healthcare system.

Now that it has achieved CE marking, European patients with a positive FIT score could subsequently be given the blood-based Nu.QTM Colorectal Cancer Screening Triage Test and then only be referred for colonoscopy if the combined test results indicate that it is necessary; thus potentially reducing colonoscopy referrals by up to 25%.

There are organized colorectal cancer screening programs in 14 of the 28 EU states with a further 10 states offering some form of public or privately accessible screening. Volition has identified the initial target governments for its launch in Europe and then intends to roll out the Nu.QTM test across further territories as part of a five year plan.

VolitionRx shares were up 4.4% to $4.77 on Tuesday.

Quick facts: VolitionRx

Price: 4.55 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $186.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

6 days, 15 hours ago

2 min read